Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute ...

Chronic myeloid leukaemia (CML) is a clonal haematopoietic stem cell disorder driven by the BCR–ABL fusion gene, which produces a constitutively active tyrosine kinase. This aberrant protein fosters ...

In nine patients with chronic lymphocytic leukemia that responded to the noncovalent BTK inhibitor pirtobrutinib and then developed resistance, analysis revealed a number of new mutations in the BTK ...

BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced ...

Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly for those with actionable ...

BTK inhibitors have transformed B-cell malignancy treatment, with distinct resistance mechanisms linked to specific inhibitors. Covalent inhibitors often lead to BTK C481 mutations, while non-covalent ...

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...

A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study. This is an ASCO Meeting ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tyrosine kinase inhibitors (TKIs) are emerging as a ...

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody. Data from the MARIPOSA study (NCT04487080) support this newest approval, and ...